Clindamycin Resistance in Staphylococcus aureus: Brief overview

Abstract

Inducible clindamycin resistance in Staphylococcus aureus presents a significant clinical challenge, potentially leading to treatment failure in infections where clindamycin is a preferred therapeutic option. This resistance phenotype is primarily mediated by erm (erythromycin ribosomal methylase) genes, which modify the bacterial ribosome, conferring cross-resistance to both macrolides (like erythromycin) and lincosamides (like clindamycin). Unlike constitutive resistance, where erm genes are continuously expressed, inducible resistance is triggered by exposure to a macrolide inducer, most commonly erythromycin. This mechanism involves a translational attenuation system where a leader peptide regulates erm gene expression. In the absence of an inducer, the leader peptide maintains the mRNA in a conformation that inhibits erm expression. However, upon exposure to a macrolide, the antibiotic interacts with the ribosome stalled on the leader peptide, causing a conformational change in the mRNA that permits erm gene translation and subsequent methylase production. The D-zone test, a phenotypic assay recommended by the Clinical and Laboratory Standards Institute (CLSI), is the standard method for detecting inducible clindamycin resistance. A flattened or "D-shaped" zone of inhibition around the clindamycin disk adjacent to an erythromycin disk indicates a positive result. Molecular methods, such as PCR amplification of erm genes, offer greater sensitivity and specificity. The clinical implications of undetected inducible resistance are serious, especially in severe infections where clindamycin's excellent tissue penetration is advantageous. Treatment failure and the potential selection for constitutive resistance during therapy underscore the importance of accurate detection. Strategies to combat this resistance include routine D-zone testing, judicious antibiotic stewardship, robust infection control measures, development of novel antibiotics, and exploration of alternative therapies. Understanding the molecular basis, detection methods, and clinical implications of inducible clindamycin resistance is crucial for effective management of staphylococcal infections.